It is a CMS-related access pathway that may help certain eligible Medicare beneficiaries access GLP-1 medications during a temporary bridge period
As such, payers should consider: Starting members on tailored weight loss solutions before authorizing GLP-1 treatment coverage Covering holistic programs inclusive of GLP-1 therapies Including conditional terms that provide short-term coverage for GLP-1 patients and Transition patients on to longer-term sustainable programs, such as: Newtopias GLP-1 Sustain is a habit-changing platform that ensures short-term GLP-1 benefits last through long-term change, supporting an eventual positive ROI
Among other things, GLP1 regulates blood glucose levels by stimulating glucose-dependent insulin release and decreasing glucagon secretion, promotes proliferation of pancreatic b-cells, slows gastric emptying, and inhibits satiety and food intake through effects on central nervous system centers 13,14
It is not safe to quit the medication on their own for people managing type 2 diabetes
The combination of adequate protein and consistent resistance training ensures that the weight you lose comes primarily from fat stores rather than lean tissue
Fifty-nine (79%) patients had a diabetes diagnosis
